Affordable Access

Publisher Website

Typhoid fever vaccination strategies.

  • Date, Kashmira A1
  • Bentsi-Enchill, Adwoa2
  • Marks, Florian3
  • Fox, Kimberley4
  • 1 Global Immunization Division, Centers for Disease Control and Prevention (CDC), Atlanta, GA 30329-4027, USA. Electronic address: [email protected]
  • 2 Department of Immunization, Vaccines and Biologicals (IVB), World Health Organization (WHO), Geneva, Switzerland. , (Switzerland)
  • 3 International Vaccine Institute, Kwanak PO Box 14, Seoul 151-600, Republic of Korea. , (North Korea)
  • 4 World Health Organization Regional Office for the Western Pacific, United Nations Avenue, 1000 Manila, Philippines. , (Philippines)
Published Article
Publication Date
Jun 19, 2015
33 Suppl 3
DOI: 10.1016/j.vaccine.2015.04.028
PMID: 25902360


Typhoid vaccination is an important component of typhoid fever prevention and control, and is recommended for public health programmatic use in both endemic and outbreak settings. We reviewed experiences with various vaccination strategies using the currently available typhoid vaccines (injectable Vi polysaccharide vaccine [ViPS], oral Ty21a vaccine, and injectable typhoid conjugate vaccine [TCV]). We assessed the rationale, acceptability, effectiveness, impact and implementation lessons of these strategies to inform effective typhoid vaccination strategies for the future. Vaccination strategies were categorized by vaccine disease control strategy (preemptive use for endemic disease or to prevent an outbreak, and reactive use for outbreak control) and vaccine delivery strategy (community-based routine, community-based campaign and school-based). Almost all public health typhoid vaccination programs used ViPS vaccine and have been in countries of Asia, with one example in the Pacific and one experience using the Ty21a vaccine in South America. All vaccination strategies were found to be acceptable, feasible and effective in the settings evaluated; evidence of impact, where available, was strongest in endemic settings and in the short- to medium-term. Vaccination was cost-effective in high-incidence but not low-incidence settings. Experience in disaster and outbreak settings remains limited. TCVs have recently become available and none are WHO-prequalified yet; no program experience with TCVs was found in published literature. Despite the demonstrated success of several typhoid vaccination strategies, typhoid vaccines remain underused. Implementation lessons should be applied to design optimal vaccination strategies using TCVs which have several anticipated advantages, such as potential for use in infant immunization programs and longer duration of protection, over the ViPS and Ty21a vaccines for typhoid prevention and control.

Report this publication


Seen <100 times